| Literature DB >> 35059462 |
Venera Shakirova1, Ilseyar Khaertynova1, Maria Markelova2, Rachael Tarlinton3, Jerzy Behnke4, Ekaterina Martynova2, Ekaterina Garanina2, Albert Rizvanov2, Svetlana Khaiboullina2.
Abstract
Nephropathia epidemica (NE) is a zoonotic disease caused by hantaviruses transmitted from rodents, endemic in the Republic of Tatarstan, Russia. The disease presents clinically with mild, moderate, and severe forms, and time-dependent febrile, oliguric, and polyuric stages of the disease are also recognized. The patient's cytokine responses have been suggested to play a central role in disease pathogenesis; however, little is known about the different patterns of cytokine expression in NE in cohorts of different ages and sexes. Serum samples and clinical records were collected from 139 patients and 57 controls (healthy donors) and were used to analyze 48 analytes with the Bio-Plex multiplex magnetic bead-based antibody detection kits. Principal component analysis of 137 patient and 55 controls (for which there was full data) identified two components that individually accounted for >15% of the total variance in results and together for 38% of the total variance. PC1 represented a proinflammatory TH17/TH2 cell antiviral cytokine profile and PC2 a more antiviral cytokine profile with patients tending to display one or the other of these. Severity of disease and stage of illness did not show any correlation with PC1 profiles; however, significant differences were seen in patients with high PC1 profiles vs. lower for a number of individual clinical parameters: High PC1 patients showed a reduced number of febrile days, but higher maximum urine output, higher creatinine levels, and lower platelet levels. Overall, the results of this study point towards a stronger proinflammatory profile occurring in younger NE patients, this being associated with markers of acute kidney injury and low levels of high-density cholesterol. This is consistent with previous work indicating that the pathology of NE is immune driven, with an inflammatory immune response being associated with disease and that this immune response is more extreme in younger patients.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35059462 PMCID: PMC8766188 DOI: 10.1155/2022/4685288
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic, clinical, and laboratory information for NE.
| Variables | Value |
|---|---|
| Age (years) | 38 ± 12.9 |
| Sex (M/F) | 117/22 |
| Age M (years) | 38.4 ± 12 |
| Age F (years) | 47.4 ± 14 |
| Mild form HFRS (%) | 10.07 |
| Moderate form HFRS (%) | 58.23 |
| Severe form HFRS (%) | 23.72 |
| Mild HFRS M/F | 17/8 (14.5%/36.4%) |
| Moderate HFRS M/F | 71/11 (60.7%/50%) |
| Severe HFRS M/F | 29/3 (24.8%/13.6%) |
| Antibody titer (1st) | 1 : 200 |
| Antibody titer (2nd) | 1 : 800 |
| Hospitalization (days) | 9.4 ± 4.7 |
Prevalence of clinical symptoms according to severity of disease and age.
| Symptom | Symptom class | Symptom severity prevalence (CL95) | Sex | Sex prevalence (CL95) | Age class | Age prevalence (CL95) |
|---|---|---|---|---|---|---|
| Nose bleed | 1 | 4.0 (0.21-19.56) | Male | 16.2 (11.35-22.47) | 1 | 17.2 (9.27-29.07) |
| 2 | 9.9 (4.44-19.94) | Female | 0.0 (0.0-15.17) | 2 | 7.7 (3.59-15.03) | |
| 3 | 30.3 (18.62-44.92) | |||||
| ∗ | ∗ | NS | ||||
| Petechia | 1 | 0.0 (0.0-13.36) | Male | 18.8 (13.51-25.42) | 1 | 23.0 (13.63-35.72) |
| 2 | 4.9 (1.47-13.63) | Female | 4.5 (0.24-22.21) | 2 | 5.8 (2.46-12.31) | |
| 3 | 57.6 (42.87-71.27) | |||||
| ∗∗∗ | NS | ∗∗ | ||||
| Scleral bleed | 1 | 0.0 (0.0-13.36) | Male | 6.8 (3.89-11.63) | 1 | 6.9 (2.45-16.61) |
| 2 | 2.5 (0.38-10.00) | Female | 0.0 (0.0-15.17) | 2 | 3.8 (1.27-9.77) | |
| 3 | 18.2 (9.31-31.91) | |||||
| ∗∗ | NS | NS | ||||
| Bleeding | 1 | 4.0 (0.21-19.56) | Male | 29.1 (22.67-36.33) | 1 | 32.2 (21.14-45.12) |
| 2 | 17.3 (9.56-28.64) | Female | 4.5 (0.24-22.21) | 2 | 13.5 (7.73-21.77) | |
| 3 | 60.0 (45.93-74.10) | |||||
| ∗∗∗ | ∗∗ | NS | ||||
| Cough | 1 | 28.0 (13.37-47.97) | Male | 5.1 (2.66-9.50) | 1 | 3.4 (0.69-11.86) |
| 2 | 7.4 (2.85-16.76) | Female | 31.8 (15.18-54.65) | 2 | 19.2 (12.41-28.34) | |
| 3 | 0.0 (0.0-8.04) | |||||
| ∗∗∗ | ∗∗ | ∗ | ||||
| Diarrhea | 1 | 12.0 (3.36-30.31) | Male | 35.0 (28.14-42.53) | 1 | 35.6 (24.26-48.58) |
| 2 | 32.1 (21.46-44.55) | Female | 31.8 (15.18-54.65) | 2 | 23.1 (15.34-32.69) | |
| 3 | 42.2 (28.73-57.13) | |||||
| NS | ∗∗ | NS | ||||
| Vomiting | 1 | 8.0 (1.45-25.59) | Male | 35.0 (28.14-42.53) | 1 | 41.4 (29.15-54.36) |
| 2 | 34.6 (23.60-47.03) | Female | 31.8 (15.18-54.65) | 2 | 23.1 (15.34-32.69) | |
| 3 | 54.5 (39.81-68.37) | |||||
| ∗∗ | NS | ∗ | ||||
| Nausea | 1 | 36.0 (19.57-56.08) | Male | 57.3 (49.76-64.51) | 1 | 41.4 (29.15-54.36) |
| 2 | 48.1 (35.63-60.69) | Female | 31.8 (15.18-54.65) | 2 | 23.1 (15.34-32.69) | |
| 3 | 78.8 (64.27-88.59) | |||||
| ∗∗ | NS | ∗ | ||||
| Abdominal pain | 1 | 28.0 (13.37-47.97) | Male | 67.5 (60.08-74.20) | 1 | 70.1 (57.20-80.62) |
| 2 | 59.3 (46.76-71.06) | Female | 27.3 (12.61-50.00) | 2 | 46.2 (36.45-56.34) | |
| 3 | 90.0 (78.91-96.71) | |||||
| ∗∗∗ | ∗∗ | ∗ | ||||
| Back pain | 1 | 44.0 (25.60-64-25) | Male | 65.8 (58.32-72.55) | 1 | 69.0 (56.05-79.75) |
| 2 | 63.0 (50.48-74.10) | Female | 59.1 (38.26-77.78) | 2 | 57.7 (47.53-67.39) | |
| 3 | 84.8 (71.35-93.03) | |||||
| ∗∗ | NS | NS | ||||
| Anuria | 1 | 0.0 (0.0-13.36) | Male | 14.5 (9.91-20.59) | 1 | 17.2 [9.27-29.07) |
| 2 | 0.0 (0.0-6.07) | Female | 4.5 (0.24-22.21) | 2 | 5.8 (2.46-12.31) | |
| 3 | 54.5 (39.81-68.37) | |||||
| ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||
| Oliguria | 1 | 20.0 (8.23-39.84) | Male | 72.6 (65.46-78.85) | 1 | 75.9 [63.12-85.47) |
| 2 | 70.4 (57.93-80.52) | Female | 45.5 (26.05-66.17) | 2 | 55.8 (45.60-65.46) | |
| 3 | 100.0(91.96-100.0) | |||||
| ∗ | NS | ∗ | ||||
| Fog eye | 1 | 16.0 (5.66-35.74) | Male | 54.7 (47.19-62.00) | 1 | 59.8 (46.79-72.00) |
| 2 | 44.4 (32.65-56.96) | Female | 13.6 (3.83-33.82) | 2 | 28.8 (20.64-38.90) | |
| 3 | 81.8 (68.09-90.69) | |||||
| ∗∗∗ | ∗∗∗ | ∗∗∗ | ||||
∗ P = 0.05 − 0.01, ∗∗P = 0.099 − 0.001, and ∗∗∗P < 0.001. For severity classes: 1, mild; 2, moderate; and 3, severe. The sample sizes for each class were 25, 81, and 33, respectively. Number of male patients = 117 and females = 22. Number of patients for age classes 1 (≤40 years old) and 2 (>40 years old) were 87 and 52, respectively. Prevalence is the percentage (%) of subjects showing the symptom in the relevant data subset. Cl95 are the 95% confidence limits. For further details, see text.
Mean values (±S.E.M.) for all cytokines and receptors and the arithmetic difference between the mean values of patients and control subjects, in order of the magnitude of the change.
| Patients | Controls | Mean difference | X change | Mann–Whitney | |
|---|---|---|---|---|---|
| ( | ( | Patients minus controls | Patients/controls |
| |
| IL-1 | 0 62 ± 0.08 | 1.292 ± 0.12 |
|
| 0.0001∗ |
| CCL27 | 69.89 ± 7.03 | 125.19 ± 10.00 |
|
| 0.0001∗ |
| CXCL12 | 45.85 ± 9.41 | 36.284 ± 6.14 | 9.563 |
| 0.38318 |
| CXCL1 | 65.07 ± 6.034 | 51.481 ± 4.88 | 13.585 |
| 0.66127 |
| CCL7 | 29.12 ± 2.75 | 18.724 ± 3.04 | 10. 394 |
| 0.02323∗ |
| IL-8 | 63.04 ± 12.26 | 37.918 ± 15.57 | 25.123 |
| 0.00011∗ |
| IL-16 | 215.12 ± 34.78 | 122.418 ± 9.91 | 92.703 |
| 0.04059∗ |
| TNF | 2.23 ± 1.16 | 1.196 ± 0.27 | 1.035 |
| 0.23723 |
| SCF | 72.24 ± 7.04 | 33.774 ± 2.39 | 38.464 |
| 0.00066∗ |
| IFN- | 21.574 ± 3.40 | 8.958 ± 0.90∗ | 12.616 |
| 0.00012∗ |
| TRAIL | 43.553 ± 4.61 | 16.397 ± 2.52 | 27.156 |
| 0.00002∗ |
| IL-3 | 201.265 ± 26.20 | 66.724 ± 5.96 | 134.541 |
| 0.00015∗ |
| IFN- | 100.881 ± 15.60 | 32.643 ± 4.32 | 68.238 |
| 0.0001∗ |
| IL-18 | 27.441 ± 3.10 | 8.631 ± 1.48 | 18.78 |
| 0.0001∗ |
| IL- 12p40 | 288.664 ± 32.77 | 88.116 ± 12.51 | 200.548 |
| 0.0001∗ |
| MIF | 518.034 ± 65.86 | 145.137 ± 25.43 | 372.897 |
| 0.0001∗ |
| LIF | 8.739 ± 2.68 | 2.404 ± 0.44∗ | 6.335 |
| 0.00004∗ |
| M-CSF | 5.809 ± 2.02 | 1.491 ± 0.14 | 4.318 |
| 0.0001∗ |
| G-CSF | 32.999 ± 2.22 | 8.074 ± 0.92 | 24.925 |
| 0.0001∗ |
| HGF | 402.173 ± 37.50 | 97.191 ± 13.56 | 304.982 |
| 0.0001∗ |
| IL-1 ra | 141.589 ± 30.78 | 31.442 ± 5.42 | 110.147 |
| 0.0001∗ |
| IL-2ra | 133.927 ± 15.07 | 28.862 ± 3.24 | 105.065 |
| 0.0001∗ |
| SCGF - b | 8486.585 ± 868.14 | 1564.75 ± 242.42 | 6921.838 | 5.42 | 0.0001∗ |
| CCL11 | 89.706 ± 10.47 | 15.50 ± 2.90 | 74.21 | 5.79 | 0.0001∗ |
| CCL2 | 89.357 ± 25.09 | 13.02 ± 1.33 | 76.34 | 6.85 | 0.0001∗ |
| IL-7 | 14.519 ± 3.14 | 2.08 ± 0.40 | 12.44 | 6.98 | 0.0001∗ |
| IL-5 | 8.067 ± 1.19 | 1.02 ± 0.24 | 7.043 | 7.88 | 0.0001∗ |
| GM-CSF | 23.25 ± 4.03 | 2.58 ± 0.69 | 20.67 | 9.01 | 0.0001∗ |
| IL-15 | 53.60 ± 13.06 | 5.40 ± 0.86 | 48.196 | 9.92 | 0.0001∗ |
| IL-12(p70) | 38.73 ± 5.5 | 3.73 ± 0.48 | 35 |
| 0.0001∗ |
| TNF- | 43.66 ± 9.10 | 4.17 ± 0.76 | 39.495 |
| 0.0001∗ |
| VEGF | 175.55 ± 25.20 | 15.15 ± 2.45 | 160.402 |
| 0.0001∗ |
|
| 8.54 ± 3.96 | 0.73 ± 0.06 | 7.809 |
| 0.0001∗ |
| IL-6 | 39.42 ± 5.95 | 2.90 ± 0.65 | 36.516 |
| 0.0001∗ |
| CXCL9 | 1797.09 ± 253.08 | 124.22 ± 18.93 | 1672.868 |
| 0.0001∗ |
| FGF b | 19.53 ± 2.12 | 1.29 ± 0.31 | 18.233 |
| 0.0001∗ |
| IL-2 | 29.14 ± 9.54 | 1.78 ± 0.30 | 27.357 |
| 0.0001∗ |
| IL-10 | 58.92 ± 11.58 | 3.56 ± 0.65 | 55.361 |
| 0.0001∗ |
| IL-4 | 19.01 ± 2.54 | 1.10 ± 0.09 | 17.906 |
| 0.0001∗ |
| IL-17 | 42.65 ± 8.87 | 2.27 ± 0.56 | 40.376 |
| 0.0001∗ |
| IL-1 | 15.81 ± 2.07 | 0.81 ± 0.15 | 15.007 |
| 0.0001∗ |
| IL-9 | 96.2 ± 22.78 | 3.50 ± 0.51 | 92.698 |
| 0.0001∗ |
| IL-13 | 36.93 ± 5.71 | 1 34 ± 0.13 | 35.588 |
| 0.0001∗ |
| CCL3 | 47.83 ± 8.62 | 0.97 ± 0.34 | 46.857 |
| 0.0001∗ |
| CCL5 | 3062.01 ± 398.29 | 60.99 ± 8.72 | 3001.024 |
| 0.0001∗ |
| PDGF-bb | 8105.64 ± 5756.86 | 144.56 ± 23.81 | 7961.073 |
| 0.0001∗ |
| CXCL10 | 3497.04 ± 390.01 | 49.05 ± 7.17 | 3447.989 |
| 0.0001∗ |
| CCL4 | 1020.56 ± 144.66 | 10.27 ± 2.13 | 1010.289 |
| 0.0001∗ |
n: numbers of control subjects in this case is 56. Mean difference: the arithmetic difference between the mean level of each cytokine in patients and controls (patient value minus control value). Numbers in italic are negative values indicating that the level of the cytokine was higher in controls relative to patients. Those in black show cytokine levels higher in patients compared to controls. X change: the ratio of the mean value in patients and that in controls (patient value divided by the control value). Here, numbers in italic have values less than 1, indicating that the level of the cytokine in each case was lower in patients than in controls. Numbers in bold show cytokine levels > 1 to 5 times higher in patients relative to controls. Numbers in black show cytokine levels > 5 to 10 times higher in patients relative to controls and those in bold italic show cytokine levels > 10 times higher in patients relative to controls. ∗Significantly different cytokines between NE and controls, P < 0.05, Mann–Whitney U test P < 0.05.
Figure 1The proportional contribution of each cytokine/receptor to the two principal components: PC1 and PC2.
Figure 2Frequency and age distribution of PC1 and PC2 in NE and controls. Frequency of PC1 (a) and PC2 (b) distributions in NE and controls. Frequency of PC1 (c) and PC2 (d) distributions based on age of NE and controls. For details of the statistical analysis, see the text.
Figure 3The relationship of PC1 to PC2 responses. Because of the tight clustering of control values with some overlapping values from patients in the bottom left hand corner of (a). This section is magnified in (b).
Figure 4Heat map analysis of serum cytokine difference based on age of NE patient.
Figure 5Measures of pathology in control subjects (green columns, labelled 0) and in patients (white columns, labelled 1-4), according to four ranges of PC1 and PC2. The sample sizes are given in respective columns in the top two panels, while in those below only if they differed from those in the top panel. Ka − 1 = potassium.